Weight-Loss Medicine Advertising: What the ASA’s First Ban Means for Pharmacies
The ASA banned its first ever ads for oral weight-loss medicines this week, and the MHRA came out publicly in support of the ruling. Simple Online Pharmacy had invited people to join a waitlist for an oral treatment before it was even licensed in the UK, and Pharmacy Online ran a website pop-up and paid social ads for the oral Wegovy tablet after it moved to prescription-only status. Three more rulings landed against MedExpress, Juniper and Care Pharmacy for ads that never named a product at all, which is the bit I think most pharmacy teams will find uncomfortable. The ASA’s reasoning was that it looks at the overall impression an ad creates, not just whether a banned term or product name appears in the copy.
I spend a fair bit of my time running distance-selling pharmacy websites through my own compliance audit tooling, built against GPhC’s February 2025 guidance (as well as other sources), and this is exactly the kind of thing it’s designed to catch. It’s never the obvious stuff that trips a site up. Nobody’s writing “buy your Medicines here” in plain text anymore. There’s a waitlist signup, countdown pop-up, a “coming soon” page that’s really a pre-order form, all of which create consumer demand for a prescription-only medicine before a prescriber has ever been involved, and that’s precisely what the MHRA’s spokesperson flagged when he said stimulating demand for a new prescription medicine isn’t permitted, full stop.
What strikes me is that this isn’t a one-off. MHRA issued a near-identical warning to two other pharmacies back in the spring over weight-loss injection adverts, and the pattern’s just repeated itself with the oral versions now reaching the market. Each time a new form of these medicines gets licensed, a chunk of the sector seems to treat the advertising rules as something to relearn from scratch rather than a principle that applies regardless of the delivery format.
If I were auditing your site this week, I’d be looking less at whether you’ve named the drug and more at whether a reasonable person would read the page as information or as an invitation to buy. Waitlists, pre-order pop-ups, before-and-after framing, even the tone of a “notify me” button, all of it factors into that overall impression test, and it’s a harder line to hold than most website teams expect once you’ve actually got clinic throughput to think about.
More information:
https://www.itv.com/news/2026-10-06/watchdog-bans-first-ads-for-oral-weight-loss-medicines
